Intravenous Immunoglobulin Market Summary

• The Intravenous Immunoglobulin market in the 7MM is valued at approximately USD 7,384 million in 2025
  The Intravenous Immunoglobulin market is projected to grow at a CAGR of 6.9%, reaching USD 13,496 million by 2034 in leading countries (US, EU4, UK and Japan).

Intravenous Immunoglobulin Market and Epidemiology Analysis

• The Intravenous Immunoglobulin Market Size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• Intravenous Immunoglobulin companies play a key role in treating immune disorders, offering innovative therapies for patients worldwide. Leading Intravenous Immunoglobulin companies include Shanghai RAAS Blood Products Co. Ltd, Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bayer AG, Bio Products Laboratory Ltd, Biotest AG, CSL Behring, and others.

Intravenous Immunoglobulin Market size and forecast

• 2025 Intravenous Immunoglobulin Market Size: USD 7,384 million
• 2034 Projected Intravenous Immunoglobulin Market Size: USD 13,496 million
• Intravenous Immunoglobulin Growth Rate (2025-2034): 6.9% CAGR
• Largest Intravenous Immunoglobulin Market: United States

Download the Sample PDF to Get More Insight @ Intravenous Immunoglobulin Market Forecast

Key factors Driving Intravenous Immunoglobulin (IvIg) market 

Growing Intravenous Immunoglobulin Patient Pool

The IVIG market is underpinned by a large and expanding target patient pool across multiple disease areas. In the US alone, 2024 data indicate around 203K patients with primary immunodeficiency diseases, 58K with ITP, 21K with CIDP, and 1.8K with MMN. This significant and diverse patient population continues to expand due to improved diagnostic capabilities, rising disease awareness, and the increasing clinical acceptance of IVIG in both approved and off-label settings. 

Key Drug Approvals Shaping the IVIG Market

IVIG therapy iA strong portfolio of established and emerging players shapes the competitive landscape in IVIGs already approved for indications such as immune thrombocytopenic purpura, Guillain-Barré syndrome, Kawasaki’s disease, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. In addition to these approved uses, IVIG is extensively prescribed off-label for a wide spectrum of neurological, hematological, and dermatological conditions, further strengthening its role in clinical practice. Products such as BIVIGAM, which generated USD 50 million in the US in 2024, highlight the strong commercial relevance of this class.

Increasing IVIG Clinical and Commercial Activity

The competitive landscape in IVIG is shaped by a strong portfolio of established and emerging players. Key companies such as Shanghai RAAS Blood Products Co. Ltd, Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bayer AG, Bio Products Laboratory Ltd, Biotest AG, CSL Behring, Grifols SA, Kedrion SpA, ADMA Biologics Inc., and others are actively driving market growth through product development, plasma collection network expansion, and advanced manufacturing capabilities.

DelveInsight's "Intravenous Immunoglobulin Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Intravenous Immunoglobulin, historical and forecasted epidemiology as well as the Intravenous Immunoglobulin therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Intravenous Immunoglobulin market report provides current treatment practices, emerging drugs, Intravenous Immunoglobulin market share of the individual therapies, current and forecasted Intravenous Immunoglobulin market Size from 2020 to 2034, segmented by seven major markets. The Report also covers current Intravenous Immunoglobulin treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Intravenous Immunoglobulin market.

Intravenous Immunoglobulin Understanding

The DelveInsight’s Intravenous Immunoglobulin market report gives a thorough understanding of the Intravenous Immunoglobulin by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Intravenous Immunoglobulin Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Intravenous Immunoglobulin.

Intravenous Immunoglobulin Treatment

It covers the details of conventional and current medical therapies available in the Intravenous Immunoglobulin market for the treatment of the condition. It also provides Intravenous Immunoglobulin treatment algorithms and guidelines in the United States, Europe, and Japan. Intravenous Immunoglobulin clinical trials are advancing rapidly, evaluating its safety and effectiveness in treating autoimmune disorders, neurological conditions, and immune deficiencies, offering new therapeutic hope for affected patients worldwide.

Intravenous Immunoglobulin Epidemiology 

The Intravenous Immunoglobulin epidemiology section provides insights about the historical and current Intravenous Immunoglobulin patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Intravenous Immunoglobulin market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings from Intravenous Immunoglobulin Epidemiological Analyses and Forecast

The disease epidemiology covered in the report provides historical as well as forecasted Intravenous Immunoglobulin epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Intravenous Immunoglobulin Epidemiology Segmentation

• Prevalent and diagnosed cases in the 7MM
• Age-specific segmentation in the 7MM
• Gender-specific segmentation in the 7MM
• Indication-wise segmentation in the 7MM

Intravenous Immunoglobulin Drug Analysis

The drug chapter segment of the Intravenous Immunoglobulin report encloses the detailed analysis of Intravenous Immunoglobulin marketed drugs and late-stage (Phase-III and Phase-II) Intravenous Immunoglobulin pipeline drugs. It also helps to understand the Intravenous Immunoglobulin clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The Intravenous Immunoglobulin drugs market is expanding rapidly due to rising autoimmune disease cases, growing elderly populations, and increased awareness, driving demand for effective immune-modulating therapies worldwide.

Intravenous Immunoglobulin Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Intravenous Immunoglobulin treatment.

Intravenous Immunoglobulin Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Intravenous Immunoglobulin treatment.

Intravenous Immunoglobulin Market Outlook

The Intravenous Immunoglobulin market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Intravenous Immunoglobulin market trends by analyzing the impact of current Intravenous Immunoglobulin therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Intravenous Immunoglobulin market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Intravenous Immunoglobulin market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Intravenous Immunoglobulin market in 7MM is expected to witness a major change in the study period 2020-2034.

The United States Intravenous Immunoglobulin Market Outlook

This section provides the total Intravenous Immunoglobulin market size and market size by therapies in the United States.

EU-5 Countries Intravenous Immunoglobulin Market Outlook

The total Intravenous Immunoglobulin market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Intravenous Immunoglobulin Market Outlook

The total Intravenous Immunoglobulin market size and market size by therapies in Japan is also mentioned.

Intravenous Immunoglobulin Drugs Uptake

This section focuses on the rate of uptake of the potential Intravenous Immunoglobulin drugs recently launched in the Intravenous Immunoglobulin market or expected to get launched in the market during the study period 2020-2034. The analysis covers Intravenous Immunoglobulin market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Intravenous Immunoglobulin Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Intravenous Immunoglobulin market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Intravenous Immunoglobulin Pipeline Development Activities

The Intravenous Immunoglobulin pipeline report provides insights into different Intravenous Immunoglobulin clinical trials within Phase II, and Phase III stage. It also analyses Intravenous Immunoglobulin key players involved in developing targeted therapeutics.

Intravenous Immunoglobulin Pipeline Development Activities

The Intravenous Immunoglobulin clinical trials analysis report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Intravenous Immunoglobulin emerging therapies.

Reimbursement Scenario in Intravenous Immunoglobulin

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Latest KOL-Views on Intravenous Immunoglobulin

To keep up with current Intravenous Immunoglobulin market trends, we take KOLs and SMEs ' opinion working in the Intravenous Immunoglobulin domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Intravenous Immunoglobulin market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Intravenous Immunoglobulin Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Intravenous Immunoglobulin Market Report

• The report covers the descriptive overview of Intravenous Immunoglobulin, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Intravenous Immunoglobulin epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Intravenous Immunoglobulin is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Intravenous Immunoglobulin market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Intravenous Immunoglobulin market

Intravenous Immunoglobulin Market Report Highlights

• In the coming years, the Intravenous Immunoglobulin market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The Intravenous Immunoglobulin companies and academics are working to assess challenges and seek opportunities that could influence Intravenous Immunoglobulin R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Intravenous Immunoglobulin. The launch of emerging therapies will significantly impact the Intravenous Immunoglobulin market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Intravenous Immunoglobulin
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Intravenous Immunoglobulin Market Report Insights

• Intravenous Immunoglobulin Patient Population
• Intravenous Immunoglobulin Therapeutic Approaches
• Intravenous Immunoglobulin Pipeline Analysis
• Intravenous Immunoglobulin Market Size and Trends
• Intravenous Immunoglobulin Market Opportunities
• Impact of upcoming Intravenous Immunoglobulin Therapies

Intravenous Immunoglobulin Market Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Intravenous Immunoglobulin Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Intravenous Immunoglobulin Drugs Uptake

Intravenous Immunoglobulin Market Report Assessment

• Current Intravenous Immunoglobulin Treatment Practices
• Intravenous Immunoglobulin Unmet Needs
• Intravenous Immunoglobulin Pipeline Product Profiles
• Intravenous Immunoglobulin Market Attractiveness
• Intravenous Immunoglobulin Market Drivers
• Intravenous Immunoglobulin Market Barriers

Key Questions Answered In The Intravenous Immunoglobulin Market Report

Intravenous Immunoglobulin Market Insights:

• What was the Intravenous Immunoglobulin drug class share (%) distribution in 2024 and how it would look like in 2034?
• What would be the Intravenous Immunoglobulin total market size as well as market size by therapies across the 7MM during the forecast period (2025-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Intravenous Immunoglobulin market size during the forecast period (2025-2034)?
• At what CAGR, the Intravenous Immunoglobulin market is expected to grow by 7MM during the forecast period (2025-2034)?
• What would be the Intravenous Immunoglobulin market outlook across the 7MM during the forecast period (2025-2034)?
• What would be the Intravenous Immunoglobulin market growth till 2034, and what will be the resultant market Size in the year 2034?
• How would the Intravenous Immunoglobulin unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Intravenous Immunoglobulin Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Intravenous Immunoglobulin?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Intravenous Immunoglobulin patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Intravenous Immunoglobulin in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Intravenous Immunoglobulin?
• Out of all 7MM countries, which country would have the highest prevalent population of Intravenous Immunoglobulin during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2025-2034)?

Current Intravenous Immunoglobulin Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Intravenous Immunoglobulin treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Intravenous Immunoglobulin in the USA, Europe, and Japan?
• What are the Intravenous Immunoglobulin marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many Intravenous Immunoglobulin companies are developing therapies for the treatment of Intravenous Immunoglobulin?
• How many therapies are in-development by each company for Intravenous Immunoglobulin treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Intravenous Immunoglobulin treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Intravenous Immunoglobulin therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Intravenous Immunoglobulin and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Intravenous Immunoglobulin?
• What are the global historical and forecasted market of Intravenous Immunoglobulin?

Reasons to buy Intravenous Immunoglobulin Market Forecast Report

• The report will help in developing business strategies by understanding trends shaping and driving the Intravenous Immunoglobulin market
• To understand the future market competition in the Intravenous Immunoglobulin market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Intravenous Immunoglobulin in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Intravenous Immunoglobulin market
• To understand the future market competition in the Intravenous Immunoglobulin market